Neuroplast Develops Safer Stem Cell Therapy For Spinal Injuries
Unique Autologous Approach
Executive Summary
Emerging Company Profile: The Dutch biotech is working on a more streamlined autologous stem cell therapy for traumatic spinal cord injury, an indication currently dominated by allogeneic treatments which present safety issues.
You may also be interested in...
Stada Poised To Launch As Calliditas Finally Wins EU Nod For Tarpeyo
The Swedish biotech’s patience paid off as it received a positive EU CHMP opinion on its rare nephrology drug Tarpeyo following delays related to manufacturing questions.
Enanta’s Path Forward Uncertain After RSV Failure
The US biotech’s RSV treatment candidate has failed a Phase II study in low-risk patients leaving some experts skeptical of its hopes for potential improved performance in a high-risk setting.
Gene Therapy Biotechs Treating Sanfilippo Syndrome Hit Cash Crunch
Despite promising clinical data and solid regulatory plans, biotech firms hoping to address the unmet need in Sanfilippo Syndrome through gene therapy are facing financial struggles.